All Relations between Tuberous Sclerosis and mtor

Publication Sentence Publish Date Extraction Date Species
\\xc5\\x9eule Ye\\xc5\\x9fil, Bur\\xc3\\xa7ak Kurucu, Melda Berber Hamamc\\xc4\\xb1, \\xc5\\x9e\\xc3\\xbckriye Y\\xc4\\xb1lmaz, G\\xc3\\xbcrses \\xc5\\x9eahi. Treatment of tuberous sclerosis complex manifestations in children with mTOR inhibitors. Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery. 2023-11-10. PMID:37947859. treatment of tuberous sclerosis complex manifestations in children with mtor inhibitors. 2023-11-10 2023-11-20 Not clear
He Min, Linhua Yang, Xinsen Xu, Yajun Geng, Fatao Liu, Yingbin Li. SNHG15 promotes gallbladder cancer progression by enhancing the autophagy of tumor cell under nutrition stress. Cell cycle (Georgetown, Tex.). 2023-11-08. PMID:37937948. mechanistically, snhg15 could interact with ampk and facilitate the phosphorylation of ampk to tuberous sclerosis complex tsc2, resulting in mtor suppression and autophagy enhancement, and finally, conferring the gbc cell sustain proliferation under nutrition stress. 2023-11-08 2023-11-20 Not clear
Mengling Liu, Jiayou Ye, Xiaoling Yo. An updated meta-analysis of effectiveness and safety of mTOR inhibitors in the management of tuberous sclerosis complex patients. Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery. 2023-10-31. PMID:37906297. an updated meta-analysis of effectiveness and safety of mtor inhibitors in the management of tuberous sclerosis complex patients. 2023-10-31 2023-11-08 Not clear
Rajal B Shah, Rohit Mehr. Renal Cell Carcinoma Associated With TSC/MTOR Genomic Alterations: An Update on its Expanding Spectrum and an Approach to Clinicopathologic Work-up. Advances in anatomic pathology. 2023-10-30. PMID:37899532. renal cell carcinoma (rcc) with tuberous sclerosis complex (tsc)/mammalian target of rapamycin (mtor) pathway-related genomic alterations have been classically described in hereditary tsc syndrome setting involving germline mutations, whereby cells with a bi-allelic inactivation of genes originate tumors in a classic tumor-suppressor "two-hit" knudson paradigm. 2023-10-30 2023-11-08 Not clear
Paolo Curatolo, Mirte Scheper, Leonardo Emberti Gialloreti, Nicola Specchio, Eleonora Aronic. Is tuberous sclerosis complex-associated autism a preventable and treatable disorder? World journal of pediatrics : WJP. 2023-10-25. PMID:37878130. tuberous sclerosis complex (tsc) is a genetic disorder caused by inactivating mutations in the tsc1 and tsc2 genes, causing overactivation of the mechanistic (previously referred to as mammalian) target of rapamycin (mtor) signaling pathway in fetal life. 2023-10-25 2023-11-08 Not clear
Muhammad Haseeb, Priyanka Sachdev, Mary Sravani, Chandana Tadigotla, Naga Anjani Bhaskar Srinivas Sunkara, Nikhil Gadyalpati. Malignant Perivascular Epithelioid Cell Neoplasm of Left Kidney Treated With Targeted Therapy: A Rare Case Report. Cureus. vol 15. issue 8. 2023-09-11. PMID:37692712. these tumors occur due to tuberous sclerosis complex gene mutations leading to upregulation and overexpression\xc2\xa0of the mammalian target of rapamycin (mtor). 2023-09-11 2023-10-07 Not clear
Aashil A Batavia, Dorothea Rutishauser, Bettina Sobottka, Peter Schraml, Niko Beerenwinkel, Holger Moc. Biallelic ELOC-Inactivated Renal Cell Carcinoma: Molecular Features Supporting Classification as a Distinct Entity. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. vol 36. issue 8. 2023-08-21. PMID:37088333. eloc-mutated (elongin c-mutated) renal cell carcinoma containing biallelic eloc inactivations with chromosome 8q deletions is considered a novel subtype of renal cancer possessing a morphologic overlap with ccrcc, renal cell carcinoma (rcc) with fibromyomatous stroma exhibiting tuberous sclerosis complex (tsc)/mammalian target of rapamycin (mtor) mutations, and clear cell papillary tumor. 2023-08-21 2023-09-07 Not clear
Gurneel K Dhanesar, Harish Rengarajan, Baidarbhi Chakrabort. Malignant Perivascular Epithelioid Cell Tumor of the Uterus. Cureus. vol 15. issue 7. 2023-08-14. PMID:37575749. they belong to the family of mesenchymal tumors and include angiomyolipomas, clear cell sugar tumors of the lung, and pecomas not otherwise specified (nos).\xc2\xa0tuberous sclerosis complex 1 (tsc1) and tuberous sclerosis complex 2 (tsc2) gene mutation is associated with pecoma, which causes hyperactivation of the mammalian target of rapamycin (mtor) signaling pathway. 2023-08-14 2023-08-16 Not clear
Konstantinos Melanis, Maria-Ioanna Stefanou, Konstantinos M Themistoklis, Themistoklis Papasileka. mTOR pathway - a potential therapeutic target in stroke. Therapeutic advances in neurological disorders. vol 16. 2023-08-14. PMID:37576547. mtor is a serine/threonine kinase that composes two protein complexes, mtor complex 1 (mtorc1) and mtor complex 2 (mtorc2), and is regulated by other proteins such as the tuberous sclerosis complex. 2023-08-14 2023-08-16 Not clear
Roberto Previtali, Giorgia Prontera, Enrico Alfei, Luisa Nespoli, Silvia Masnada, Pierangelo Veggiotti, Savina Mannarin. Paradigm shift in the treatment of tuberous sclerosis: effectiveness of everolimus. Pharmacological research. 2023-08-07. PMID:37549757. tuberous sclerosis complex is caused by the disinhibition of the protein mtor (mammalian target of rapamycin). 2023-08-07 2023-08-14 Not clear
Jami Kronick, Manal Y Gabril, Andrew A Hous. Microscopic Kidney Disease in Tuberous Sclerosis Complex and Treatment With mTOR Inhibition. American journal of kidney diseases : the official journal of the National Kidney Foundation. 2023-08-02. PMID:37532078. microscopic kidney disease in tuberous sclerosis complex and treatment with mtor inhibition. 2023-08-02 2023-08-14 Not clear
Marjan Taherian, Paria Bayati, Mohammad-Ali Assarehzadegan, Mansoureh Soleimani, Hadi Poormoghim, Nazanin Mojtabav. Insights into Overlappings of Fibrosis and Cancer: Exploring the Tumor-related Cardinal Genes in Idiopathic Pulmonary Fibrosis. Iranian journal of allergy, asthma, and immunology. vol 22. issue 2. 2023-07-27. PMID:37496412. gene expression analyses indicated a significant elevation of regulatory associated protein of mtor (raptor), ras homolog enriched in brain (rheb), s6 kinase 1, and eukaryotic translation initiation factor 4e-binding protein 1 (4ebp1), as well as a significant reduction of vegfa, tuberous sclerosis complex (tsc2), and lrp1; no changes were observed in the tsc1 mrna level. 2023-07-27 2023-08-14 mouse
Aline Grosskopf Monich, Mariana Faucz Munhoz da Cunha, Fellype Carvalho Barret. mTOR inhibitors are the first-choice therapy for renal angiomyolipomas secondary to tuberous sclerosis. Jornal brasileiro de nefrologia. 2023-07-27. PMID:37497829. mtor inhibitors are the first-choice therapy for renal angiomyolipomas secondary to tuberous sclerosis. 2023-07-27 2023-08-14 Not clear
Kellen D Winden, Truc T Pham, Nicole A Teaney, Juan Ruiz, Ryan Chen, Cidi Chen, Mustafa Sahi. Increased degradation of FMRP contributes to neuronal hyperexcitability in tuberous sclerosis complex. Cell reports. vol 42. issue 8. 2023-07-26. PMID:37494191. tuberous sclerosis complex (tsc) and fragile x syndrome are associated with alterations in the mechanistic target of rapamycin (mtor) and fragile x messenger ribonucleoprotein 1 (fmrp), which have been implicated in the development of asd. 2023-07-26 2023-08-14 human
Wencheng Fu, Geng W. Design of negative-regulating proteins of Rheb/mTORC1 with much reduced sizes of the tuberous sclerosis protein complex. Protein science : a publication of the Protein Society. 2023-07-18. PMID:37462942. the tuberous sclerosis protein complex (tscc) is a master negative regulator of the mtorc1 signaling pathway through hydrolyzing the gtp loaded on the small gtpase rheb, which is a key activator of mtor. 2023-07-18 2023-08-14 human
Sayg\\xc4\\xb1n Y\\xc4\\xb1ld\\xc4\\xb1r\\xc4\\xb1m, Ebru Aypar, Bur\\xc3\\xa7a Ayd\\xc4\\xb1n, Canan Aky\\xc3\\xbcz, Hayrettin Hakan Aykan, \\xc4\\xb0lker Ertu\\xc4\\x9frul, Tevfik Karag\\xc3\\xb6z, Dursun Aleha. Cardiac rhabdomyomas: clinical progression, efficacy and safety of everolimus treatment. The Turkish journal of pediatrics. vol 65. issue 3. 2023-07-03. PMID:37395967. everolimus, a mechanistic target of rapamycin (mtor) inhibitor, can be used in the treatment of rhabdomyomas seen in tuberous sclerosis complex. 2023-07-03 2023-08-14 Not clear
Simone Bonazzi, Audrey Gray, Noel M Thomsen, Jonathan Biag, Nancy Labbe-Giguere, Erin P Keaney, Hasnain A Malik, Yingchuan Sun, Jill Nunez, Rajeshri G Karki, Mark Knapp, Robert Elling, John Fuller, Gwynn Pardee, Lucas Craig, Ketthsy Capre, Sarah Salas, Aakruti Gorde, Guiqing Liang, Danuta Lubicka, Stephanie M McTighe, Carleton Goold, Shanming Liu, Lin Deng, Jin Hong, Alexander Fekete, Pascal Stadelmann, Wilfried Frieauff, Azeddine Elhajouji, Daniel Bauer, Andreas Lerchner, Branko Radetich, Pascal Furet, Grazia Piizzi, Doug Burdette, Christopher J Wilson, Stefan Peukert, Lawrence G Hamann, Leon O Murphy, Daniel Curti. Identification of Brain-Penetrant ATP-Competitive mTOR Inhibitors for CNS Syndromes. Journal of medicinal chemistry. 2023-07-03. PMID:37399505. the allosteric inhibitor of the mechanistic target of rapamycin (mtor) everolimus reduces seizures in tuberous sclerosis complex (tsc) patients through partial inhibition of mtor functions. 2023-07-03 2023-08-14 Not clear
Aishwarya Ramamurthy, Gemma Louise Carvil. Raptor Preys on mTOR Imbalance in Tuberous Sclerosis. Epilepsy currents. vol 23. issue 3. 2023-06-19. PMID:37334409. raptor preys on mtor imbalance in tuberous sclerosis. 2023-06-19 2023-08-14 Not clear
Elisabetta Chiaradia, Ingrid Miller, Giovanni Renzone, Alessia Tognoloni, Alice Polchi, Federico De Marco, Brunella Tancini, Andrea Scaloni, Alessandro Magin. Proteomic analysis of murine Tsc1-deficient neural stem progenitor cells. Journal of proteomics. 2023-05-19. PMID:37207814. significance: tuberous sclerosis complex (tsc) is a multisystemic disorder caused by inactivating mutations of tsc1 or tsc2 genes, which induce overactivation of the mtor component. 2023-05-19 2023-08-14 Not clear
Uchenna Unachukwu, Jarrod Sonett, Denzel Woode, Takayuki Shiomi, Kiran Chada, Jeanine M D'Armient. Tyrosine Kinase Inhibitors Diminish Renal Neoplasms in a Tuberous Sclerosis Model via induction of Apoptosis. Molecular cancer therapeutics. 2023-05-01. PMID:37127876. tuberous sclerosis complex (tsc) tumors are presently incurable despite a cytostatic response to mtor pathway inhibition since recurrence of disease occurs after discontinuation of treatment. 2023-05-01 2023-08-14 mouse